📄 medicine

Changes in clinical, biochemical and quality of life measures in patients transferring from daytime hemodialysis sessions to night-time sessions – A short-term pilot prospective study

This six-month prospective pilot study found that transitioning from daytime to night-time hemodialysis significantly improved dialysis adequacy and reduced severe pain and skin problems, although overall quality of life, sleep parameters, and biochemical markers remained unchanged.

Original authors: Alia Nabila Tun-Ismail, Kamal Sud, Raymond Lin, Sarah So

Published 2026-07-06

📖 4 min read☕ Coffee break read

CC BY 4.0

Original authors: Alia Nabila Tun-Ismail, Kamal Sud, Raymond Lin, Sarah So

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

Imagine your kidneys are like a highly efficient water filtration system in a house. When they stop working, you need an external machine (dialysis) to do the filtering for you. Usually, this machine runs during the day for about four hours, three times a week. It's like having a plumber come in for a quick, intense fix every few days.

This study is about testing a different schedule: Night-Time Hemodialysis (NHD). Instead of a quick daytime fix, patients let the machine run while they sleep, for longer stretches of time (up to 8 hours). Think of it as switching from a "power wash" to a "slow, steady drip" that runs overnight.

Here is what the researchers at Nepean Hospital in Australia found when they watched 19 patients make this switch for six months.

The Setup: Who and How?

The researchers took 19 adults who were already used to the standard daytime dialysis and asked them to try the night shift. To be eligible, patients had to be generally healthy, able to walk on their own, and not need special breathing machines while they slept.

The Good News: The Machine Worked Better

When you run a filter longer, it usually catches more dirt. The study confirmed this:

Cleaning Power: The "cleaning score" (called Kt/V) went up significantly. The machine was doing a better job of clearing waste from the blood.
More Time: Patients spent more time on the machine (about 5 hours instead of 4.5).
More Water Removal: The machine was able to pull out more excess fluid from the body, which is like draining a flooded basement more effectively.

The Symptom Report: What Changed?

The researchers asked the patients, "How do you feel?" using specific checklists for pain, sleep, and daily life.

1. The "Itch" and "Ache" Got Better
This was the biggest win.

Pain: Fewer patients reported having "severe" pain. It's like turning down the volume on a loud, annoying noise.
Skin: Fewer people reported severe skin problems (like itching or dryness). In dialysis, skin issues often happen because toxins build up; since the night machine cleaned the blood more thoroughly, the skin felt better.

2. The Sleep Question
A common worry is: "If I sleep with a machine hooked to me, will I sleep worse?"

The Result: Surprisingly, sleep quality didn't get worse. The patients' sleep scores stayed about the same. They didn't report more trouble sleeping than they did during the day.
However: There was a slight increase in reports of feeling "drowsy" or wasting time during the day. It's possible that because they were sleeping with a machine, they felt a bit groggy the next day, even if their actual sleep quality was fine.

3. The "No Change" Zone
Not everything changed, and that's okay.

Blood Numbers: Things like potassium, calcium, and blood pressure didn't change much. The researchers think this is because the study only lasted six months (a short time in medical terms) and the patients were already doing reasonably well before they started.
Overall Happiness: When asked to rate their overall quality of life on a scale of 1 to 10, the average score didn't go up or down. It stayed the same.

The Dropouts

Three out of the 19 patients decided to go back to the daytime schedule. Why?

One was worried about the safety of traveling at night.
One had trouble sleeping with the machine.
One didn't say why.
The other 16 patients stuck with the night shift.

The Bottom Line

Think of this study as a "test drive" of a new car model. The researchers found that driving the "Night-Time" model:

Cleaned the engine better (better waste removal).
Fixed some specific squeaks and rattles (less pain and skin itching).
Didn't break the car (no more accidents or bad side effects).
Didn't necessarily make the ride feel "faster" or "happier" overall (quality of life scores stayed the same).

The authors conclude that switching to night dialysis can help with specific, annoying symptoms like pain and itching, but they need to study more people to be sure. They didn't claim it cures everything or that everyone should switch, just that it works well for some specific problems.

Technical Summary: Changes in Clinical, Biochemical, and Quality of Life Measures in Patients Transferring to Night-Time Hemodialysis

Problem Statement

While longer hemodialysis (HD) treatment sessions are associated with improved clinical outcomes, global implementation is constrained by cost, availability, and system resource limitations. These constraints often result in high patient-to-chair ratios, compromising care delivery, safety, and quality of life (QOL). Night-time Hemodialysis (NHD) offers a potential solution by utilizing existing infrastructure to administer longer sessions overnight, thereby expanding capacity and cost-effectiveness. Although NHD is hypothesized to provide clinical benefits through improved solute clearance and cardiovascular metrics, and to minimize disruption to employment and social activities, the impact on symptom burden and QOL remains unclear. Previous investigations have been limited by heterogeneity in measurement scales, the use of unvalidated tools for renal populations, and a lack of validated sleep assessments. Furthermore, concerns regarding sleep quality as a barrier to NHD continuation have not been rigorously assessed using validated scores.

Methodology

The authors conducted a six-month, prospective, observational pilot study at Nepean Hospital, a metropolitan tertiary hospital in Western Sydney, Australia.

Study Population: The cohort consisted of 19 adult patients transitioning from conventional daytime HD to in-center NHD. Inclusion criteria required patients to be established on maintenance HD for over three months, medically stable, independently ambulant, and free from cognitive impairment or disruptive behavior. Patients requiring sleep-related medical equipment (e.g., CPAP) were excluded.
Intervention: Patients transitioned to NHD with session durations potentially increased to a maximum of eight hours, determined by nephrologist recommendation and patient agreement.
Data Collection:
- Clinical & Biochemical: Data were extracted from electronic medical records (EMR) and the Renal Information System Catalogue (RISC). Parameters included Kt/V, urea reduction ratio (URR), ultrafiltration volumes, blood pressure, and biochemical markers (potassium, calcium, phosphate, albumin, PTH, ALP, hemoglobin).
- Quality of Life (QOL) & Symptoms: Assessed using the Integrated Palliative Outcome Scale-Renal (IPOS-Renal) and the EuroQol 5D-5L (EQ-5D-5L) at baseline, one month, three months, and six months.
- Sleep Quality: Assessed using the Functional Outcomes of Sleep Questionnaire (FOSQ-10).
- Safety: Adverse events were tracked via Medical Emergency Team (MET) and Rapid Response (RR) calls.
Statistical Analysis: Continuous variables were analyzed using paired t-tests, and categorical variables using chi-square tests. To accommodate the small dataset, symptom severity scales were grouped into three categories for analysis.

Key Contributions

This study contributes to the literature by:

Validated Multi-Domain Assessment: Unlike previous studies that relied on composite scores or unvalidated surveys, this study utilized instruments validated specifically for renal populations (IPOS-Renal, EQ-5D-5L) and a validated sleep questionnaire (FOSQ-10).
Specific Symptom Breakdown: The research provides a granular analysis of specific symptoms (e.g., pain, skin problems, drowsiness) rather than relying solely on global QOL scores.
Prospective Design: The study employs a prospective observational design, tracking patients from the point of transition to NHD over a six-month period.
Safety and Tolerability: It documents adverse events and functional status changes, addressing safety concerns regarding overnight dialysis.

Results

Of the 19 patients recruited, 15 (79%) remained on NHD at six months; three patients returned to daytime HD due to safety concerns, sleep difficulties, or undisclosed reasons.

Dialysis Parameters: There were statistically significant improvements in dialysis efficacy. Kt/V increased from a median of 1.27 to 1.51 ( $p=0.003$ ). The median actual session length increased from 4 to 5 hours ( $p=0.001$ ), and the mean ultrafiltration volume increased from 3.0L to 3.5L ( $p=0.01$ ).
Biochemistry: No statistically significant differences were observed in serum potassium, phosphate, calcium, albumin, PTH, ALP, or hemoglobin levels at six months compared to baseline.
Symptoms (IPOS-Renal):
- Improvements: There was a statistically significant reduction in the proportion of patients reporting severe pain (26.3% to 6.7%, $p=0.01$ ) and skin problems ( $p=0.01$ ). The proportion of patients reporting severe difficulty sleeping also decreased significantly ( $p=0.05$ ).
- Worsening: There was a statistically significant increase in the proportion of patients reporting mild to moderate or severe drowsiness ( $p=0.02$ ) and wasting more than half a day per week ( $p=0.02$ ).
Quality of Life (EQ-5D-5L): The "ability to perform usual activities" domain showed a statistically significant reduction in difficulty ( $p=0.02$ ), though the absolute clinical significance was noted as minimal. There was no statistically significant change in the overall self-rated QOL score ( $p=0.89$ ).
Sleep (FOSQ-10): There were no statistically significant differences in FOSQ-10 components or the aggregate summary score between baseline and six months ( $p=0.08$ ).
Safety: The median number of adverse events (MET/RR calls) remained at 0 for both pre- and post-transition periods ( $p=0.25$ ).

Significance and Claims

The authors conclude that NHD may be associated with improvements in select troublesome symptoms, specifically pain and skin conditions, after six months of transition. The study demonstrates that NHD successfully delivers longer treatment sessions with improved small solute clearance (Kt/V) without a significant increase in adverse events or deterioration in functional status.

However, the authors maintain a modest stance regarding the broader implications:

Symptom Specificity: While improvements in pain and skin symptoms were observed, the study was not powered to examine these improvements specifically, and the mechanisms (e.g., improved solute clearance vs. other factors) remain to be fully elucidated.
Generalizability: The findings may not be generalizable to older or more comorbid patients, as the study cohort had a median age of 49 and a high Karnofsky performance score (80), indicating a relatively healthy and self-caring population compared to the general HD demographic.
Future Directions: The authors assert that these findings should be explored with larger prospective studies to confirm the effects on specific symptomatology and to determine the underlying mechanisms. They do not claim NHD as a universal solution for all QOL metrics, noting that self-rated QOL and sleep parameters largely remained unchanged or showed mixed results.